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Abstract
Background: To evaluate the impact of four different rectum contouring techniques and rectal
toxicities in patients with treated with 3D conformal radiotherapy (3DCRT).
Methods: Clinical and dosimetric data were evaluated for 94 patients who received a total dose
3DCRT of 70 Gy, and rectal doses were compared in four different rectal contouring techniques:
the prostate-containing CT sections (method 1); 1 cm above and below the planning target volume
(PTV) (method 2); 110 mm starting from the anal verge (method 3); and from the anal verge to the
sigmoid flexure (method 4). The percentage of rectal volume receiving RT doses (30–70 Gy) and
minimum, mean rectal doses were assessed.
Results: Median age was 69 years. Percentage of rectal volume receiving high doses (≥ 70 Gy) were
higher with the techniques that contoured smaller rectal volumes. In methods 2 and 3, the
percentage of rectal volume receiving ≥ 70 Gy was significantly higher in patients with than without
rectal bleeding (method 2: 30.8% vs. 22.5%, respectively (p = 0.03); method 3: 26.9% vs. 18.1%,
respectively (p = 0.006)). Mean rectal dose was significant predictor of rectal bleeding only in
method 3 (48.8 Gy in patients with bleeding vs. 44.4 Gy in patients without bleeding; p = 0.02).
Conclusion: Different techniques of rectal contouring significantly influence the calculation of
radiation doses to the rectum and the prediction of rectal toxicity. Rectal volume receiving higher
doses (≥ 70 Gy) and mean rectal doses may significantly predict rectal bleeding for techniques
contouring larger rectal volumes, as was in method 3.
Background
Prostate cancer is a radio-responsive tumor with a well-
defined dose-response relationship [1,2]. Higher radio-
therapy (RT) doses have been associated with better bio-
chemical control rates and fewer distant relapses [1,3].
Those findings support the suggestion that enhanced sur-
vival rates may be achievable with an improvement in
local control. However, the use of higher RT doses is lim-
ited by an increased risk of complications in adjacent nor-
mal tissues. In this setting, more sophisticated techniques
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such as three dimensional conformal RT (3DCRT), inten-
sity modulated RT (IMRT), and tomotherapy allow more
precise treatment planning with better sparing of the nor-
mal tissues [4], which yields higher local control with sig-
nificant reduction in both acute and late complications[5]
Nevertheless, the use of higher RT doses beyond the con-
ventional doses has been demonstrated to cause a moder-
ate increase in the dose-limiting, late rectal toxicity,
mainly manifested by rectal bleeding [6,7].
The major predictor of rectal bleeding is the volume of the
rectum included in the high dose region [8,9], and the
correlation between rectal bleeding rates and the irradi-
ated rectal volume has been well established [9-12]. Fur-
thermore dose-volume histograms (DVH) served as useful
tools in demonstrating this significant relationship.
Despite its extreme importance, no universally accepted
method has been established for rectal contouring in RT
planning for prostatic carcinomas. The length of rectum
contoured has been defined in different ways by different
authors. Examples of these definitions include: 1 cm
above and below the planning target volume
(PTV)[13,14], the length of the rectum in prostate-con-
taining tomography sections [15], 110 mm of rectum
starting from anal verge [12,16], or the anal verge to the
rectosigmoid flexure [10,17-19].
One important drawback of using different rectal defini-
tions and contouring methods is the resultant difficulty in
interpreting the outcomes of different studies. Thus, we
planned to compare four different rectal volume defini-
tion techniques and dependent irradiated percent rectal
volumes on predicting rectal toxicity in patients with
localized prostate cancer treated with 3DCRT, which will
be a guide for evaluating the rectal toxicity wherein the
rectal contouring technique used.
Methods
Patient Data
A total of 118patients with histological proof of prostate
adenocarcinoma was treated with 3D-CRT between Janu-
ary 2007 and February 2008 in the Department of Radia-
tion Oncology at Baskent University. We analyzed clinical
and dosimetric data of 94 eligible patients. Eligibility cri-
teria were as follows: Eastern Cooperative Oncology
Group performance status (PS) of 0 to 2; age between 18
and 70 years; non-prostatectomised; no prior chemother-
apy or abdominal irradiation; no distant metastasis; no
contraindication for RT. Invariably, all eligible patients
were treated with the same technique and the same doses,
and any deviations from either the technique or dose were
reasons for exclusion from the study. The clinical and
dosimetric records of patients with stage T1c-T3 (Ameri-
can Joint Committee on Cancer, 1997 staging system)
prostate cancer were used in this analysis. Prostate speci-
mens were scored with the Gleason grading system.
According to our current protocol, all patients were
treated with 3 months of neoadjuvant total androgen
blockage prior to planned irradiation. Baskent Univer-
sity's Institutional Review Board approved this study
design.
Treatment Planning
As part of treatment planning, all patients underwent a CT
scan with 2.5-mm slice thickness. During the scan,
patients were in supine with their feet fixed in a commer-
cially available knee support device, an emptied rectum,
and comfortably full bladder. Patients were asked to
empty their rectum before treatment, no enema or other
laxatives were used before planning CT and during treat-
ment. The CTV was defined as the entire prostate and sem-
inal vesicles. A 1-cm margin was added to the CTV to
define the planning target volume (PTV). The treatment
volume included an additional 0.7-cm margin for beam
penumbra in all directions, except for the posterior mar-
gin, which overlaps the rectum; thus, posteriorly, a 0.5-cm
margin was added for reducing rectal toxicity. The iso-
center was positioned in the center of the PTV and beams
were shaped with multi-leaf collimators (MLC; Varian
DHX 3323, Varian Medical Systems, Palo Alto, California,
USA).
The exposed rectum was defined in four different ways for
all 94 patients as depicted in Table 1. All target and organ
at risk volumes were defined and contoured by the same
physician. Intra-observer variability was also assessed on
randomly selected 10 sample patients by a blind repeti-
tion of rectum contouring on randomly chosen CT scans.
The mean intra-observer variability was 0.7 mm in the cra-
nial and 0.9 mm in the caudal directions, respectively.
All treatments were planned with a six-field technique
using a treatment planning system (Eclipse®, Varian Med-
ical Systems, Palo Alto, California, USA). A total of 70 Gy
(2 Gy/fr, daily, Monday through Friday) was delivered
using 18-MV photons. Portal images obtained from the
anterior set-up and two lateral fields on the first treatment
day and once weekly, or more (if necessary), during the RT
period, were used to confirm field verifications by com-
paring them with digitally reconstructed radiographs. The
portal images were reviewed by the treating physician.
Table 1: Rectum contouring techniques
Methods Techniques
1 All prostate-containing CT sections
2 1 cm above and below PTV-containing sections
3 110 mm of rectum starting from the anal verge
4 Anal verge to the sigmoid flexureRadiation Oncology 2009, 4:14 http://www.ro-journal.com/content/4/1/14
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DVH Analysis
The dose distribution of each plan for each patient's rec-
tum was established and the doses were re-calculated for
the different rectal volumes lengths. The DVHs created for
each patient and methods were used to perform inter-
method comparisons. Our analysis included the percent
volume of rectum irradiated with certain dose levels (30
to 70 Gy, in 10 Gy increments) evident on DVHs created
for each method, and their possible predictive role on rec-
tal toxicity incidence and severity. All doses represent total
doses that have not been corrected for fractionation.
Toxicity Score
Side effects manifested within 90 days from the initiation
of RT were considered "acute", and "late" those manifest
thereafter. Rectal toxicities were graded according to the
Radiation Therapy Oncology Group (RTOG) toxicity
scores [20]. The rectal toxicity grades are: grade 1 = minor
symptoms requiring no treatment; grade 2 = symptoms
that respond to simple management; grade 3 = distressing
symptoms affecting lifestyle and necessitating hospital
admission; grade 4 = symptoms necessitating a major sur-
gical procedure (laparatomy, colostomy, long stay in hos-
pital); and grade 5 = death. Grades 1 and 2 rectal bleeding
is defined as incidental or intermittent bleeding requiring
no treatment or responding to simple outpatient manage-
ment, respectively; grade 3 rectal bleeding is defined as
bleeding that requires a blood transfusion or laser cauter-
ization.
During the RT course, all eligible patients were evaluated
on the same day of the week for toxicity scoring, unless a
patient required more frequent visits. In the medical
records, the type of toxicity and its grade, the time of
occurrence, as well as the prescribed medications and
doses were systematically reported.
Follow-up
The length of follow-up was calculated from the first date
of 3DCRT. According to the medical records, follow-up
visits included a thorough physical examination, serum
total and free prostate specific antigen (PSA), and testo-
sterone levels, complete blood count and serum biochem-
istry, and pelvic MRI every 6 months. At each visit,
detailed genitourinary and gastrointestinal system toxici-
ties were assessed. The patients were first seen 6 weeks
after the completion of RT and every 3 months or more
frequently, if necessary, thereafter.
Statistical Analysis
The dosimetric variables considered were rectal volume,
maximum and mean dose to the rectal volume (Dmax
and Dmean, respectively), and volumes (percentage and
absolute) of rectum receiving 30 Gy, 40 Gy, 50 Gy, 60 Gy,
and 70 Gy. For each patient and each technique, DVHs
were compared for both dosimetric assessment and their
predictive value on rectal toxicity. The Fisher's exact test
was used to compare qualitative variables and the Stu-
dent's t means comparison test was used for continuous
variables. The median values of these differences were
compared using the Wilcoxon signed rank test to evaluate
if they were significantly different from zero. A p ≤ 0.05
(two-sided) was considered significant for all statistical
tests.
Results
Total 94 of 118 eligible patients were evaluated. 26
patients were excluded from the study, because, 16
patients were treated after radical prostatectomy, 6
patients were treated with pelvic box technique because of
lymph node metastasis, and 2 patients did not finish the
sheduled treatment (1 with myocardial infarction, 1 with
no reason). The patient and disease characteristics are
summarized in Table 2. All 94 patients were eligible for
toxicity analysis and no patient was lost to follow-up; the
median follow-up interval was 13.1 months (range: 3–
21.6 months). The treatment protocol was well tolerated
in general with no report of grade 4 or 5 acute or late tox-
icity. Sixteen patients (17%) completed the treatment
without any significant complications. Rectal toxicities of
grade 1 to 3 were reported in 34 (36%), 36 (38%), and 8
(9%) patients, respectively. Rectal bleeding was reported
in 13 (14%) patients, and were graded as grade 2 in 12
(13%), and grade 3 in the remaining 1 (1%). This latter
patient was presented at the 9th month after 3DCRT and
fared well following two courses of laser cauterization.
The median prostate and seminal vesicle volumes were 38
cm3 (range: 18–111.7 cm3) and 13 cm3 (range: 4.8–28.8
cm3), respectively. The median prostate, seminal vesicle,
and PTV doses were 69.7 Gy (range: 68.5 – 71.3 Gy), 69.8





Pretreatment PSA n (%)
≤ 10 ng/mL 37 (39)
> 10 ng/mL 57 (61)
Gleason score n (%)
6 55 (59)
7 30 (32)
83  ( 3 )
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Gy (range: 68.4 – 72.0 Gy), and 70.0 Gy (range: 68.7 –
71.5 Gy), respectively.
Table 3 shows the median rectum volumes using the dif-
ferent contouring techniques. As expected, compared to
methods 1 and 2, relatively larger rectum volumes were
contoured in methods 3 and 4. Table 4 shows the compar-
ison of rectum minimum, maximum and mean doses and
percentage of rectal volumes receiving different doses
based on these different techniques. The mean rectal
doses and percentage of rectal volumes receiving different
dose levels were higher with contouring techniques that
resulted in small rectal volumes (method 1) than with
contouring techniques that resulted in average and large
rectal volumes (method 3). Thus, for example, the mean
rectum dose and V70 were higher in method 1 (57.5 Gy
and 32.9%, respectively) than in method 3 (49.6 Gy and
24.3%, respectively).
The comparison of rectal minimum and mean doses, V30,
V40, V50, V60 and V70 Gy revealed significantly higher
doses for method 1 compared to the other methods; the
lowest mean rectal doses and percentage of rectal volumes
at different dose levels were obtained with the technique
used in method 3. The minimum and mean rectal doses
significantly differed in each method. Similarly, statisti-
cally significant differences were established for the per-
centage of rectum volumes receiving 30 Gy, 40 Gy, 50 Gy,
60 Gy, and 70 Gy, respectively.
Acute rectal toxicity was closely associated with the mean
rectum doses and V30 Gy, V40 Gy, V50 Gy, V60 Gy and
V70 Gy points for all contouring techniques. As shown in
Table 5 mean rectal doses and V70 Gy were significantly
higher in patients with Grade 2 or more rectal toxicity
compared to patients with or without Grade 1 rectal tox-
icity. The mean rectal dose in patients with Grade 2 or
more rectal toxicity was lowest in method 3 (52.4 Gy) and
highest in method 1(61.0 Gy). Likewise V70 Gy values
were higher in methods 1 and 2 (42.3% and 37.3%) com-
pared to methods 3 and 4 (32.5% and 33.4%), respec-
tively.
When rectal bleeding was evaluated Wilcoxon test
revealed that, in method 2, the percentage of rectal vol-
umes those received ≥ 70 Gy were 30.8% and 22.5% for
patients with and without rectal bleeding (p  = 0.03),
respectively. Similarly in method 3, the percentage of rec-
tal volume that received ≥ 70 Gy was 26.9% and 18.1% in
patients with and without bleeding (p = 0.006). The mean
rectal dose was found to be a significant predictor of rectal
bleeding only in method 3; mean rectal doses were 48.8
Gy and 44.4 Gy for patients with and without bleeding (p
= 0.02). No significant correlation was found for low or
moderate dose levels.
Discussion
In this study, four different rectum contouring techniques
were assessed, and the impact of the contouring tech-
niques on DVH and acute rectal toxicity and rectal bleed-
ing was evaluated. We clearly demonstrated that mean
rectal dose and rectal volume receiving a high dose (≥ 70
Gy) are the most important predictive factors for acute rec-
tal toxicity and rectal bleeding, and varies according to rec-
tal contpuring techniques. This significance was assessed
in this study with different rectum contouring techniques,
and especially the method 3 revealed a significant correla-
tion.
The primary aim of 3D-CRT in prostate carcinoma is to
maximize the therapeutic ratio to deliver an effective dose
to the tumor while maintaining an acceptable dose to the
neighboring normal tissues. In this manner, better control
of the local tumor and reduction of distant metastatic
rates can be achieved by escalating the dose beyond that
of conventional doses without additional toxicities
[9,21,22]. However, toxicities such as late rectal bleeding,
which is one of the dose-limiting complications, may pre-
vent escalation of the dose and therefore adversely affect
treatment outcomes. The volume of the rectum included
in the high dose region is the major determinant for pre-
dicting late rectal bleeding. In recent years a number of
studies evaluated the relationship between rectal toxicity
and rectal irradiation, and for this purpose rectal DVHs,
dose wall histograms (DWHs), and dose surface histo-
grams (DSHs) have been used. However, the definitions
of the affected rectum varied widely among the research-
ers [10,12-14,16-19,23], and no universally accepted,
conclusive result has been obtained with respect to
whether DVH, DSH, or DWH is the best predictor of rectal
complications, including late rectal bleeding. Nor has
such a result been obtained to determine which length of
the contoured rectum provides the best predictor of com-
plications. In this current study, we compared mean rectal
doses and percentage of rectal volumes receiving particu-
lar doses (30–70 Gy) via DVHs in most commonly used
four rectal contouring techniques to an effort to deter-
mine the best contouring technique for prediction of rec-
tal toxicity.
Table 3: The Median Rectum Volumes
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The use of different rectal contouring techniques with dif-
ferent rectal lengths and volumes yield various radiation
doses, which may result in a variety of toxicity probabili-
ties. This issue has been addressed by various authors.
One of the most important predictors of acute rectal tox-
icity and rectal bleeding is the rectal volume receiving a
high dose (60–80 Gy) [19,24,25]. Koper et al. found that
the risk of rectal bleeding increased from 10% to 63%
when the irradiated rectal volume increased from 25% to
100% [17]. In that study, the rectum was contoured from
the anal verge proximally to the sacroiliac joint. Michalski
et al., in the preliminary report of toxicity from an inter-
group trial, observed that the relative risk of developing
late gastrointestinal system toxicity was two-fold greater if
the total rectal volume receiving radiation dose exceeded
100 cm3; the rectum was contoured as a solid organ
extending from the anus to the rectosigmoid flexure [21].
In a randomized trial, Pollack et al. reported a significant
increase in rectal toxicity in patients treated with 78 Gy
compared to 70 Gy [16]. The DVH calculations were per-
formed with respect to the rectal volumes within a 11-cm
cranio-caudal segment, with no specification as to
whether the rectal contents were included. The authors
demonstrated that the 5-year risk of grade ≥ 2 rectal toxic-
ity was 37% in patients with > 25% of the rectum receiv-
ing ≥ 70 Gy compared to 13% for patients with < 25% of
the rectum receiving ≥ 70 Gy. In addition, all grade 3 com-
plications occurred when V70 exceeded 30% of the rectal
volume [9]. In this current study, we clearly demonstrated
that all grade ≥ 2 acute rectal toxicities were seen in
patients with > 30% of the rectum receiving ≥ 70 Gy
regardless of contouring techniques (Table 5). Also a sig-
nificant correlation was found between rectal bleeding
and rectal volume receiving ≥ 70 Gy for rectum contoured
in methods 2 and 3.
The mean rectal dose is another dosimetric factor that pre-
dicts rectal morbidity. Zapatero et al. demonstrated that
the mean rectal dose and V60 Gy were closely correlated
with grade 2 or worse rectal bleeding in 107 patients with
prostate cancer treated with 3DCRT [25]. They found that
patients with rectal bleeding had a mean rectal dose of 57
Gy compared with 46 Gy for those without bleeding (p <
0.0005). The rectum was contoured over 150 mm, from
the anus (at the level of the ischial tuberosities) to where
the rectosigmoid flexure could be identified. In the cur-
rent study, we found a statistically significant correlation
between rectal bleeding and mean rectal doses only when
the rectum was contoured over 110 mm starting from the
anus (method 3: 48.8 Gy for patients with rectal bleeding
and 44.4 Gy for patients without rectal bleeding (p  =
0.02)). The fact that this correlation was significant only
in method 3 may be due to the fact that this technique
contours larger rectal volumes than the other techniques
that we used. The rectum contoured in the study of Zapa-
tero et al. was even longer and the rectal volume larger
compared to those in method 3 of our study. Thus, mean
rectal doses may significantly predict rectal bleeding for
techniques contouring larger rectal volumes.
In one of the first studies that evaluated the rectal contour-
ing problem, Geinitz et al. concluded that a uniform def-
inition of the rectal volume should be established to
achieve equivalent DVH results [26]. Boehmer et al. com-
pared two different rectal contouring techniques: one
technique included the rectum bounded by two CT slices
above and below the PTV; the other technique included
the rectum from the anal verge to the sigmoid colon [27].
Furthermore, the posterior half of the rectum was con-
toured for both volumes. The first technique resulted in
significantly higher minimum and mean rectal doses than
did the second technique. The authors concluded that dif-
ferent ways of rectal contouring significantly influence cal-
culated doses to the rectum. In another study, Liu et al.
Table 4: Median Dose-Volume Histogram and Dose-Wall Histogram data for the patients treated with 3DCRT.
Method 1 Method 2 Method 3 Method 4 p
Min dose (Gy) 8.2 3.2 1.5 1.9 0.01
Mean dose (Gy) 57.5 54.0 49.6 51.1 <0.001
Max dose (Gy) 75.1 75.1 75.1 75.1 NS
V30 Gy (%) 86.7 84.5 80.6 82.1 <0.001
V40 Gy (%) 78.1 73.3 68.6 70.7 <0.001
V50 Gy (%) 70.9 64.2 55.3 59.8 <0.001
V60 Gy (%) 55.6 48.4 41.7 45.1 <0.001
V70 Gy (%) 32.9 27.9 24.3 26.5 <0.001
Table 5: Mean rectal doses and percentage of rectal volume 
receiving 70 Gy (V70 Gy) values according to acute rectal 
toxicity grade groups.










Method 1 53,4 61,0 < 0.001 27,2 42,3 < 0.001
Method 2 49,8 58,4 < 0.001 23,0 37,3 < 0.001
Method 3 44,5 52,4 < 0.001 19,8 32,5 < 0.001
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compared 6 different ways of contouring the rectum in 10
patients with prostate cancer treated with a four-field box-
technique with a total dose of 70 Gy. They concluded that
absolute rectal wall volume, in addition to percent rectal
volume, should be used in analyzing late rectal toxicity
[24].
Our study also demonstrates that the rectal DVHs vary
considerably with different rectum delineation tech-
niques. The rectum contoured in all prostate-containing
CT sections (method 1) had the largest percentage of rec-
tum receiving a specific radiation dose, since less rectum
volume was contoured. Any contouring techniques that
use a longer length of the rectum will result in a smaller
percentage of the contoured rectum receiving the radia-
tion dose. Thus, the technique that contoured a 110-mm
rectal segment from the anal verge (method 3) resulted in
lower radiation doses than the techniques that contoured
shorter segments and smaller rectal volumes. This is due
to the fact that the absolute volume of rectum receiving a
specific dose remains constant while the percentage of rec-
tal volume receiving a specific dose becomes reduced if
the total volume contoured is larger. Therefore, with dif-
ferent rectal length and volume contouring techniques,
the differences in the configurations of the different DVHs
become apparently significant.
Conclusion
In conclusion, with a relatively larger patient population,
we demonstrated that percentage of rectal volumes receiv-
ing high doses (≥ 70 Gy) and mean rectal doses which are
predictors of rectal toxicity varied in different rectum con-
touring techniques with differing DVHs. The rectal vol-
ume exposed to high RT doses (≥ 70 Gy) seems to be a
crucial determinant in predicting late rectal bleeding in
almost all contouring techniques. In method 3; in which
rectum was contoured 110 mm starting from anal verge,
rectum volume was found to be higher than other meth-
ods, and a significant importance of mean rectal dose and
percentage of rectal volume receiving >70 Gy was estab-
lished. Finally, we think that, there is an urgent need for a
universally accepted precise definition of rectal volumes
for a systematic reliable comparison of various histo-
grams.
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